Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade

 
• By John Davis

Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.  

Rocket
Alnylam's lead product has been submitted for marketing approval • Source: Shutterstock

More from Clinical Trials

More from R&D